転移性がん治療薬の世界市場レポート 2025年

転移性がん治療薬市場規模は、今後数年間で力強い成長が見込まれます。2029年の年間平均成長率（CAGR）は5.6%で750億5,000万米ドルに成長します。予測期間の成長は、プレシジョン・メディシンの進化、バイオマーカー主導型治療、リキッドバイオプシーの進歩、患者中心のアプローチ、包括的ゲノム・プロファイリングに起因すると考えられます。予測期間の主要動向には、新たな併用療法、ナノメディシンの進歩、長期生存支援、早期介入戦略、健康の公平性とアクセスなどが含まれます。

転移性がん治療薬市場の成長は、2つの重要な要因によって牽引されると予想されます。第一に、転移性がんの有病率の増加が市場拡大に寄与すると考えられます。転移性がんは、体の他の部分へのがんの進行した広がりを特徴とし、増加傾向にあります。転移性がんの症例数の増加が、さまざまなタイプの転移性がんを標的とする新規抗がん剤の開発に拍車をかけています。注目すべきは、米国国立がん研究所ジャーナルが2022年に予測した、米国における転移性乳がん、前立腺がん、肺がん、大腸がん、膀胱がん、または転移性黒色腫の患者数は、2025年までに69万人に達する見込みであることです。転移性がんの有病率の増加は、統計の増加からも明らかであり、転移性がん治療薬市場の主要促進要因となっています。

精密医療と個別化治療の進化が市場成長をさらに促進すると予想されます。精密医療は、遺伝的体質、分子プロファイル、環境、ライフスタイルなどの要素を考慮しながら、個々の患者に合わせた医療や治療を行うものです。精密医療における転移性がん治療薬の活用により、患者固有の遺伝的・分子的特徴に基づいたオーダーメイドの治療戦略が可能になります。このアプローチにより、ヘルスケアプロバイダーは、特定のがんサブタイプに対して有効である可能性が高い標的療法を特定することができ、それによって治療成績を向上させ、副作用を最小限に抑えることができます。例えば、2022年10月の個別化医療連合（Personalized Medicine Coalition）の推計によれば、様々ながんやその他の健康状態にある患者に対して、75,000以上の遺伝子検査キットと300以上の個別化治療が利用可能になるとされています。個々の患者の特性に焦点を当てた精密医療と個別化治療の進化は、転移性がん治療薬市場の重要な促進要因です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界転移性がん治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の転移性がん治療薬市場：成長率分析
• 世界の転移性がん治療薬市場の実績：規模と成長, 2019-2024
• 世界の転移性がん治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界転移性がん治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の転移性がん治療薬市場薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• HER2阻害剤
• 免疫チェックポイント阻害剤
• PARP阻害剤
• キナーゼ阻害剤
• その他の薬物クラス
• 世界の転移性がん治療薬市場がん、実績と予測, 2019-2024, 2024-2029F, 2034F
• 乳がん
• 肺がん
• 肝臓がん
• 血液がん
• 脳腫瘍
• 前立腺がん
• 膵臓がん
• その他のがん
• 世界の転移性がん治療薬市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 化学療法
• 免疫療法
• ホルモン療法
• 手術
• その他の治療法
• 世界の転移性がん治療薬市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 静脈内
• 筋肉内
• オーラル
• その他の投与経路
• 世界の転移性がん治療薬市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 専門クリニック
• その他のエンドユーザー
• 世界の転移性がん治療薬市場HER2阻害剤の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• トラスツズマブ
• アドトラスツズマブエムタンシン
• ラパチニブ
• 世界の転移性がん治療薬市場免疫チェックポイント阻害剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• PD-1阻害剤
• PD-L1阻害剤
• CTLA-4阻害剤
• 世界の転移性がん治療薬市場、PARP阻害剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• オラパリブ
• ルカパリブ
• ニラパリブ
• 世界の転移性がん治療薬市場キナーゼ阻害剤のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• EGFR阻害剤
• BRAF阻害剤
• ALK阻害剤
• 世界の転移性がん治療薬市場、その他の薬物クラスのタイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 化学療法剤
• ホルモン療法
• 標的療法

第7章 地域別・国別分析

• 世界の転移性がん治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の転移性がん治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 転移性がん治療薬市場：競合情勢
• 転移性がん治療薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson and Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bayer AG
• AstraZeneca plc
• Novartis AG
• Sanofi S.A.
• Bristol-Myers Squibb Company
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Gilead Sciences Inc.
• Amgen Inc.
• Astellas Pharma Inc.
• Eisai Co. Ltd.
• Sun Pharmaceutical Industries Ltd.
• Incyte Corporation
• Ipsen SA
• Seagen Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 転移性がん治療薬市場2029：新たな機会を提供する国
• 転移性がん治療薬市場2029：新たな機会を提供するセグメント
• 転移性がん治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Metastatic cancer therapies encompass pharmaceuticals designed to address cancer that has spread from its original site to other parts of the body. The primary objective of these medications is to target cancer cells, impeding their growth and preventing further spread.

Key categories of metastatic cancer drugs include HER2 inhibitors, immune checkpoint inhibitors, PARP inhibitors, kinase inhibitors, and others. HER2 inhibitors specifically target human epidermal growth factor receptor (HER2) to obstruct the reception of growth signals in HER2-positive cancers. These inhibitors find applications in diverse cancer types, including breast cancer, lung cancer, liver cancer, hematological cancer, brain cancer, prostate cancer, pancreatic cancer, and others. Treatment modalities involve chemotherapy, immunotherapy, hormonal therapy, surgery, and various routes of administration such as intravenous, intramuscular, and oral administration. These therapies are utilized across different healthcare settings, including hospitals, specialty clinics, and others.

The metastatic cancer drugs market research report is one of a series of new reports from The Business Research Company that provides metastatic cancer drugs market statistics, including metastatic cancer drugs industry global market size, regional shares, competitors with a metastatic cancer drugs market share, detailed metastatic cancer drugs market segments, metastatic cancer drugs market trends and opportunities, and any further data you may need to thrive in the metastatic cancer drugs industry. This metastatic cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The metastatic cancer drugs market size has grown steadily in recent years. It will grow from $58.07 billion in 2024 to $60.36 billion in 2025 at a compound annual growth rate (CAGR) of 3.9%. The growth in the historic period can be attributed to chemotherapy development, advancements in targeted therapies, immunotherapy discoveries, clinical trials success, and improved diagnosis and staging

The metastatic cancer drugs market size is expected to see strong growth in the next few years. It will grow to $75.05 billion in 2029 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to precision medicine evolution, biomarker-driven therapies, liquid biopsy advancements, patient-centric approaches, and comprehensive genomic profiling. Major trends in the forecast period include emerging combination therapies, nanomedicine advancements, long-term survivorship support, early intervention strategies, health equity and access.

The anticipated growth in the metastatic cancer drugs market is expected to be driven by two significant factors. Firstly, the increasing prevalence of metastatic cancers is poised to contribute to market expansion. Metastatic cancer, characterized by the advanced spread of cancer to other parts of the body, is on the rise. The growing number of metastatic cancer cases has spurred the development of novel cancer medications targeting various types of metastatic cancer. Notably, the Journal of the National Cancer Institute projected in 2022 that the number of individuals living with metastatic breast, prostate, lung, colorectal, or bladder cancer, or metastatic melanoma in the United States, is expected to reach 0.69 million cases by 2025. The increasing prevalence of metastatic cancers, as evidenced by rising statistics, is a key driver for the metastatic cancer drugs market.

The evolution of precision medicine and personalized therapies is anticipated to further propel market growth. Precision medicine involves tailoring medical care and treatment to individual patients, taking into account factors such as genetic makeup, molecular profile, environment, and lifestyle. The utilization of metastatic cancer drugs in precision medicine allows for tailored treatment strategies based on the unique genetic and molecular characteristics of patients. This approach enables healthcare providers to identify targeted therapies that are more likely to be effective against specific cancer subtypes, thereby enhancing treatment outcomes and minimizing adverse effects. For example, estimates from the Personalized Medicine Coalition in October 2022 indicated that over 75,000 genetic testing kits and 300 personalized treatments will be available for individuals with various cancers and other health conditions. The evolution of precision medicine and personalized therapies, by focusing on individual patient characteristics, is a significant driver for the metastatic cancer drugs market.

Product innovations have become a prominent trend in the metastatic cancer drugs market, with major players focusing on developing novel therapies to strengthen their market position. For example, in May 2022, Roche Pharma, a Switzerland-based leader in biotechnology and pharmaceuticals, launched a new drug for breast cancer treatment. PHESGO is the first fixed-dose formulation in oncology that combines the monoclonal antibodies Perjeta and Herceptin with hyaluronidase, enabling subcutaneous injection alongside IV chemotherapy. This groundbreaking treatment reduces in-clinic time by 90%, greatly enhancing patient convenience. Roche Pharma India CEO V. Simpson Emmanuel emphasized that this innovation allows patients to spend more time on activities they enjoy, thereby improving their overall quality of life.

Major companies in the metastatic cancer drugs market are actively involved in developing novel drugs such as ZN-A-1041, an oral breast cancer medicine. ZN-A-1041, an orally administered selective tyrosine kinase inhibitor, specifically targets the human epidermal growth factor receptor 2 (HER2) and is designed to penetrate the blood-brain barrier. This drug has demonstrated potential in treating or preventing the onset of brain metastases in HER2-positive metastatic breast cancer patients. For instance, in May 2022, F. Hoffmann-La Roche AG launched ZN-A-1041, which can cross the blood-brain barrier to treat breast tumors that have spread to the brain.

In March 2023, Pfizer Inc., a US-based pharmaceutical company, confirmed its acquisition plans with Seagen Inc. for $43 billion. This strategic move is part of Pfizer's broader strategy to expand its oncology portfolio and solidify its position as a global leader in the oncology division. The acquisition of Seagen Inc., a biotechnology company specializing in antibody-based cancer medicines, complements Pfizer's existing portfolio across solid tumors and hematologic malignancies.

Major companies operating in the metastatic cancer drugs market include Pfizer Inc., Johnson and Johnson Services Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, AstraZeneca plc, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Astellas Pharma Inc., Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Incyte Corporation, Ipsen SA, Seagen Inc., Exelixis Inc., Zymeworks Inc., Karyopharm Therapeutics Inc., CRISPR Therapeutics AG, Fate Therapeutics Inc., CytomX Therapeutics Inc., Spectrum Pharmaceuticals Inc., Intellia Therapeutics Inc., GlaxoSmithKline plc, Adaptimmune Therapeutics plc

North America was the largest region in the metastatic cancer drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the metastatic cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the metastatic cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The metastatic cancer drugs market consists of sales of drugs such as capecitabine, docetaxel, eribulin, pegylated, gemcitabine, and vinorelbine. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Metastatic Cancer Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on metastatic cancer drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for metastatic cancer drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The metastatic cancer drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: HER2 Inhibitors; Immune Checkpoints Inhibitors; PARP Inhibitors; Kinase Inhibitors; Other Drug Class
• 2) By Cancer: Breast Cancer; Lung Cancer; Liver Cancer; Hematological Cancer; Brain Cancer; Prostate Cancer; Pancreatic Cancer; Other Cancers
• 3) By Treatment: Chemotherapy; Immunotherapy; Hormonal Therapy; Surgery; Other Treatments
• 4) By Route Of Administration: Intravenous; Intramuscular; Oral; Other Routes Of Administration
• 5) By End-Users: Hospitals; Specialty Clinics; Other End-Users
• Subsegments:
• 1) By HER2 Inhibitors: Trastuzumab; Ado-trastuzumab emtansine; Lapatinib
• 2) By Immune Checkpoint Inhibitors: PD-1 Inhibitors; PD-L1 Inhibitors; CTLA-4 Inhibitors
• 3) By PARP Inhibitors: Olaparib; Rucaparib; Niraparib
• 4) By Kinase Inhibitors: EGFR Inhibitors; BRAF Inhibitors; ALK Inhibitors
• 5) By Other Drug Classes: Chemotherapy Agents; Hormonal Therapies; Targeted Therapies
• Companies Mentioned: Pfizer Inc.; Johnson and Johnson Services Inc.; F. Hoffmann-La Roche AG; Merck & Co. Inc.; AbbVie Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Metastatic Cancer Drugs Market Characteristics

3. Metastatic Cancer Drugs Market Trends And Strategies

4. Metastatic Cancer Drugs Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Metastatic Cancer Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Metastatic Cancer Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Metastatic Cancer Drugs Market Growth Rate Analysis
• 5.4. Global Metastatic Cancer Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Metastatic Cancer Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Metastatic Cancer Drugs Total Addressable Market (TAM)

6. Metastatic Cancer Drugs Market Segmentation

• 6.1. Global Metastatic Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• HER2 Inhibitors
• Immune Checkpoints Inhibitors
• PARP Inhibitors
• Kinase Inhibitors
• Other Drug Class
• 6.2. Global Metastatic Cancer Drugs Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Breast Cancer
• Lung Cancer
• Liver Cancer
• Hematological Cancer
• Brain Cancer
• Prostate Cancer
• Pancreatic Cancer
• Other Cancers
• 6.3. Global Metastatic Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemotherapy
• Immunotherapy
• Hormonal Therapy
• Surgery
• Other Treatments
• 6.4. Global Metastatic Cancer Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravenous
• Intramuscular
• Oral
• Other Routes Of Administration
• 6.5. Global Metastatic Cancer Drugs Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Other End-Users
• 6.6. Global Metastatic Cancer Drugs Market, Sub-Segmentation Of HER2 Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Trastuzumab
• Ado-trastuzumab emtansine
• Lapatinib
• 6.7. Global Metastatic Cancer Drugs Market, Sub-Segmentation Of Immune Checkpoint Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• PD-1 Inhibitors
• PD-L1 Inhibitors
• CTLA-4 Inhibitors
• 6.8. Global Metastatic Cancer Drugs Market, Sub-Segmentation Of PARP Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Olaparib
• Rucaparib
• Niraparib
• 6.9. Global Metastatic Cancer Drugs Market, Sub-Segmentation Of Kinase Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• EGFR Inhibitors
• BRAF Inhibitors
• ALK Inhibitors
• 6.10. Global Metastatic Cancer Drugs Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemotherapy Agents
• Hormonal Therapies
• Targeted Therapies

7. Metastatic Cancer Drugs Market Regional And Country Analysis

• 7.1. Global Metastatic Cancer Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Metastatic Cancer Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Metastatic Cancer Drugs Market

• 8.1. Asia-Pacific Metastatic Cancer Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Metastatic Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Metastatic Cancer Drugs Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Metastatic Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Metastatic Cancer Drugs Market

• 9.1. China Metastatic Cancer Drugs Market Overview
• 9.2. China Metastatic Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Metastatic Cancer Drugs Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Metastatic Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Metastatic Cancer Drugs Market

• 10.1. India Metastatic Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Metastatic Cancer Drugs Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Metastatic Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Metastatic Cancer Drugs Market

• 11.1. Japan Metastatic Cancer Drugs Market Overview
• 11.2. Japan Metastatic Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Metastatic Cancer Drugs Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Metastatic Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Metastatic Cancer Drugs Market

• 12.1. Australia Metastatic Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Metastatic Cancer Drugs Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Metastatic Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Metastatic Cancer Drugs Market

• 13.1. Indonesia Metastatic Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Metastatic Cancer Drugs Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Metastatic Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Metastatic Cancer Drugs Market

• 14.1. South Korea Metastatic Cancer Drugs Market Overview
• 14.2. South Korea Metastatic Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Metastatic Cancer Drugs Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Metastatic Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Metastatic Cancer Drugs Market

• 15.1. Western Europe Metastatic Cancer Drugs Market Overview
• 15.2. Western Europe Metastatic Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Metastatic Cancer Drugs Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Metastatic Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Metastatic Cancer Drugs Market

• 16.1. UK Metastatic Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Metastatic Cancer Drugs Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Metastatic Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Metastatic Cancer Drugs Market

• 17.1. Germany Metastatic Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Metastatic Cancer Drugs Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Metastatic Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Metastatic Cancer Drugs Market

• 18.1. France Metastatic Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Metastatic Cancer Drugs Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Metastatic Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Metastatic Cancer Drugs Market

• 19.1. Italy Metastatic Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Metastatic Cancer Drugs Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Metastatic Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Metastatic Cancer Drugs Market

• 20.1. Spain Metastatic Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Metastatic Cancer Drugs Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Metastatic Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Metastatic Cancer Drugs Market

• 21.1. Eastern Europe Metastatic Cancer Drugs Market Overview
• 21.2. Eastern Europe Metastatic Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Metastatic Cancer Drugs Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Metastatic Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Metastatic Cancer Drugs Market

• 22.1. Russia Metastatic Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Metastatic Cancer Drugs Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Metastatic Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Metastatic Cancer Drugs Market

• 23.1. North America Metastatic Cancer Drugs Market Overview
• 23.2. North America Metastatic Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Metastatic Cancer Drugs Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Metastatic Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Metastatic Cancer Drugs Market

• 24.1. USA Metastatic Cancer Drugs Market Overview
• 24.2. USA Metastatic Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Metastatic Cancer Drugs Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Metastatic Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Metastatic Cancer Drugs Market

• 25.1. Canada Metastatic Cancer Drugs Market Overview
• 25.2. Canada Metastatic Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Metastatic Cancer Drugs Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Metastatic Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Metastatic Cancer Drugs Market

• 26.1. South America Metastatic Cancer Drugs Market Overview
• 26.2. South America Metastatic Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Metastatic Cancer Drugs Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Metastatic Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Metastatic Cancer Drugs Market

• 27.1. Brazil Metastatic Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Metastatic Cancer Drugs Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Metastatic Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Metastatic Cancer Drugs Market

• 28.1. Middle East Metastatic Cancer Drugs Market Overview
• 28.2. Middle East Metastatic Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Metastatic Cancer Drugs Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Metastatic Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Metastatic Cancer Drugs Market

• 29.1. Africa Metastatic Cancer Drugs Market Overview
• 29.2. Africa Metastatic Cancer Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Metastatic Cancer Drugs Market, Segmentation By Cancer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Metastatic Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Metastatic Cancer Drugs Market Competitive Landscape And Company Profiles

• 30.1. Metastatic Cancer Drugs Market Competitive Landscape
• 30.2. Metastatic Cancer Drugs Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson and Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Metastatic Cancer Drugs Market Other Major And Innovative Companies

• 31.1. Bayer AG
• 31.2. AstraZeneca plc
• 31.3. Novartis AG
• 31.4. Sanofi S.A.
• 31.5. Bristol-Myers Squibb Company
• 31.6. Takeda Pharmaceutical Company Limited
• 31.7. Eli Lilly and Company
• 31.8. Gilead Sciences Inc.
• 31.9. Amgen Inc.
• 31.10. Astellas Pharma Inc.
• 31.11. Eisai Co. Ltd.
• 31.12. Sun Pharmaceutical Industries Ltd.
• 31.13. Incyte Corporation
• 31.14. Ipsen SA
• 31.15. Seagen Inc.

32. Global Metastatic Cancer Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Metastatic Cancer Drugs Market

34. Recent Developments In The Metastatic Cancer Drugs Market

35. Metastatic Cancer Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Metastatic Cancer Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Metastatic Cancer Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Metastatic Cancer Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer